首页> Cancer> Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial.

Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial.

导出原文传递

翻译打印收藏纠错

第一作者： David A,Reardon

第一单位： Dana-Farber Cancer Institute, Boston, Massachusetts.

作者： David A,Reardon ^[1] ; Tae Min,Kim ^[2] ; Jean-Sebastien,Frenel ^[3] ; Matteo,Simonelli ^[4] ; Juanita,Lopez ^[5] ; Deepa S,Subramaniam ^[6] ; Lillian L,Siu ^[7] ; Hui,Wang ^[8] ; Suba,Krishnan ^[9] ; Karen,Stein ^[9] ; Christophe,Massard ^[10]

作者单位： Dana-Farber Cancer Institute, Boston, Massachusetts. ^[1] Seoul National University Hospital, Seoul, South Korea. ^[2] Institut de Cancérologie de l'Ouest, Nantes, France. ^[3] Humanitas University, Department of Biomedical Sciences, Milan, Italy.;Humanitas Clinical and Research Center-IRCCS, Humanitas Cancer Center, Milan, Italy. ^[4] Drug Development Unit, Royal Marsden Hospital, Sutton, United Kingdom. ^[5] Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia. ^[6] Princess Margaret Cancer Centre, Toronto, Ontario, Canada. ^[7] MSD China, Beijing, China. ^[8] Merck & Co., Inc., Kenilworth, New Jersey. ^[9] Institut Gustave Roussy, Villejuif, France. ^[10]

关键词 glioblastoma immunotherapy pembrolizumab programmed death ligand 1 treatment outcomes

医学主题词胶质母细胞瘤(Glioblastoma);人类(Humans);肿瘤复发, 局部(Neoplasm Recurrence, Local);回顾性研究(Retrospective Studies);治疗结果(Treatment Outcome)

DOI 10.1002/cncr.33378

PMID 33496357

发布时间 2021-12-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交